GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Global Blood Therapeutics Inc (NAS:GBT) » Definitions » Cash Flow from Investing

Global Blood Therapeutics (Global Blood Therapeutics) Cash Flow from Investing : $-390.8 Mil (TTM As of Jun. 2022)


View and export this data going back to 2015. Start your Free Trial

What is Global Blood Therapeutics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Jun. 2022, Global Blood Therapeutics spent $0.4 Mil on purchasing property, plant, equipment. It gained $0.0 Mil from selling property, plant, and equipment. It spent $0.0 Mil on purchasing business. It gained $0.0 Mil from selling business. It spent $163.8 Mil on purchasing investments. It gained $29.5 Mil from selling investments. It paid $0.0Mil for net Intangibles purchase and sale. And it paid $0.0 Mil for other investing activities. In all, Global Blood Therapeutics spent $134.7 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Jun. 2022.


Global Blood Therapeutics Cash Flow from Investing Historical Data

The historical data trend for Global Blood Therapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Global Blood Therapeutics Cash Flow from Investing Chart

Global Blood Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only -35.00 -184.16 -76.86 317.31 12.11

Global Blood Therapeutics Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.75 -16.13 -17.51 -222.50 -134.66

Global Blood Therapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Global Blood Therapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2021 is calculated as:

Global Blood Therapeutics's Cash Flow from Investing for the quarter that ended in Jun. 2022 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-390.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Global Blood Therapeutics  (NAS:GBT) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Global Blood Therapeutics's purchase of property, plant, equipment for the three months ended in Jun. 2022 was $-0.4 Mil. It means Global Blood Therapeutics spent $0.4 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Global Blood Therapeutics's sale of property, plant, equipment for the three months ended in Jun. 2022 was $0.0 Mil. It means Global Blood Therapeutics gained $0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Global Blood Therapeutics's purchase of business for the three months ended in Jun. 2022 was $0.0 Mil. It means Global Blood Therapeutics spent $0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Global Blood Therapeutics's sale of business for the three months ended in Jun. 2022 was $0.0 Mil. It means Global Blood Therapeutics gained $0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Global Blood Therapeutics's purchase of investment for the three months ended in Jun. 2022 was $-163.8 Mil. It means Global Blood Therapeutics spent {stock_data.stock.currency_symbol}}163.8 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Global Blood Therapeutics's sale of investment for the three months ended in Jun. 2022 was $29.5 Mil. It means Global Blood Therapeutics gained $29.5 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Global Blood Therapeutics's net Intangibles purchase and sale for the three months ended in Jun. 2022 was $0.0 Mil. It means Global Blood Therapeutics paid $0.0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Global Blood Therapeutics's cash from discontinued investing activities for the three months ended in Jun. 2022 was 0.0 Mil. It means Global Blood Therapeutics paid $0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Global Blood Therapeutics's cash from other investing activities for the three months ended in Jun. 2022 was $-0.0 Mil. It means Global Blood Therapeutics paid $0.0 Mil for other investing activities.


Global Blood Therapeutics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Global Blood Therapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Global Blood Therapeutics (Global Blood Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
181 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.
Executives
Jeffrey S Farrow officer: Chief Financial Officer TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Nazila Habibizad officer: See Remarks C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Philip A. Pizzo director ONE COMMERCE STREET, SUITE 2550, MEMPHIS TN 38103
Scott W Morrison director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Carrie Krehlik officer: Chief Human Resources Officer 6015 COLTON BLVD, OAKLAND CA 94611
Eric Fink officer: Chief Human Resources Officer C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080
Kim Smith-whitley officer: See Remarks C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Alexis A. Thompson director C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Brian Edwin Cathers officer: Chief Scientific Officer C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080
Lesley Ann Calhoun officer: See Remarks C/O GLOBAL BLOOD THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Mark L Perry director 176 WEST BLITHEDALE AVE, MILL VALLEY CA 94941
Ted W Love director, officer: See Remarks C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Tricia Borga Suvari officer: Chief Legal Officer 3172 PORTER DRIVE PALO ALTO CA 94034
Brown Willie L. Jr. director C/O GLOBAL BLOOD THERAPEUTICS, INC. 400 EAST JAMIE COURT, SUITE 101 SOUTH SAN FRANCISCO CA 94080

Global Blood Therapeutics (Global Blood Therapeutics) Headlines

From GuruFocus

GBT Announces New Employment Inducement Grants

By PurpleRose PurpleRose 07-15-2022